Experimentica is heading to BIO-Europe Spring 2025 in Milan
Come to meet us in BIO-Europe Spring 2025 in Milan! Our Executive Chairman Giedrius Kalesnykas and CBO Guillaume Demarne are attending the event on March 17-19, 2025.
Learn more
Experimentica UAB (Lithuania) receives full accreditation from AAALAC International
Experimentica UAB in Lithuania achieved a major accomplishment by receiving a full accreditation from AAALAC International for its outstanding work on animal welfare.
Learn more
Experimentica Oy Announces Appointment of New Managing Director
Experimentica Oy announces the appointment of a new Managing Director. The current CEO will transition to the role of Executive Chairman.
Learn more
Meet Us at Bio-Europe 2024!
Experimentica will be presenting preclinical ocular models at Bio-Europe 2024 in Stockholm, Nov. 4-6, 2024.
Learn more
Kon’nichiwa BioJapan 2024!
Experimentica will be presenting preclinical ocular models at BioJapan 2024 in Yokohama, Oct. 9-11, 2024.
Learn more
Meet Experimentica at the 5th Gene Therapy for Ophthalmic Disorders Summit in Boston
Experimentica attends the 5th Gene Therapy for Ophthalmic Disorders Summit in Boston, Sept. 10-12, 2024.
Learn more
Experimentica attends ARVO 2024 (booth #1440)
Experimentica is pleased to announce its participation in the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2024.
Learn more
Experimentica Ltd. renews French CIR accreditation
France's Crédit d'Impôt Recherche incentive can cover up to 30% of R&D expenses incurred by innovative French pharma and biotech companies working with Experimentica.
Learn more
Experimentica Science Day | May 26, 2023, Vilnius, LT
Experimentica Science Day: connect with top preclinical Ophthalmology Professors and Industry Experts for insights and discoveries
Learn more
Experimentica-led NeoVasculoStop Consortium Awarded 3 M€ European Innovation Council Pathfinder Grant
Focus is to develop innovative oral treatments for retinal diseases caused by neovascularization and to improve the safety of anti-angiogenic therapies for patients.
Learn more
